AbbVie Presents New Data from Two Antibody-Drug Conjugates Across Multiple Indications at ASCO 2024

Estimated read time 1 min read

In an interview with Pharm Exec Associate Editor Don Tracy, Pedro Valencia, VP, Solid Tumor Pipeline Strategy & Execution, AbbVie, discusses data presented at ASCO from ABBV-400 and ABBV-706 in multiple studies.

You May Also Like

More From Author

+ There are no comments

Add yours